Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Fineline Cube Jun 23, 2026
Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Fineline Cube Jun 24, 2026
Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Fineline Cube Jun 25, 2026
Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Fineline Cube Jun 25, 2026
Legal / IP

SAMR Imposes Penalties on Grand Pharma and WuHan Huihai for Monopoly Agreements

Fineline Cube May 29, 2023

The State Administration for Market Regulation (SAMR) has imposed administrative penalties on Grand Pharmaceutical Group...

Company Drug

Ascentage Pharma to Present Clinical Results of Four Oncology Drugs at Medical Conference

Fineline Cube May 29, 2023

Suzhou-based Ascentage Pharma (HKG: 6855) has announced its intention to present the clinical results of...

Deals Policy / Regulatory

Hainan Province and NHSA Partner to Enhance Medical Insurance Industry with Real-World Data

Fineline Cube May 26, 2023

The government of Hainan province has entered into a strategic partnership with the National Healthcare...

Company Drug

BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting

Fineline Cube May 26, 2023

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced the presentation of new data at...

Policy / Regulatory

Shanghai Market Regulation Bureau Targets Unfair Competition in Pharmaceutical Sector

Fineline Cube May 26, 2023

The Shanghai market regulation bureau has released a document aimed at cracking down on unfair...

Company Deals

TianLong Science and Technology Expands into Northern Thailand with Hepatitis Diagnostics

Fineline Cube May 26, 2023

Xi’an-based med-tech firm TianLong Science and Technology Co., Ltd has reportedly entered into a supply...

Company Drug

Chia Tai Tianqing’s TQ-B3525 Heads for Priority Review for Recurrent Follicular Lymphoma

Fineline Cube May 26, 2023

The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQ-B3525, a...

Company Drug

Sanofi Launches Soliqua for Type 2 Diabetes Treatment in China

Fineline Cube May 26, 2023

French pharmaceutical major Sanofi (NASDAQ: SNY) has announced the official market launch of Soliqua (insulin...

Company Drug

GenScript’s Legend Biotech Files Type II Variation Application for Carvykti with EMA

Fineline Cube May 26, 2023

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...

Company Drug

Takeda and HutchMed’s Fruquintinib Receives Priority Review Status from FDA

Fineline Cube May 26, 2023

Takeda (TYO: 4502) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) have provided an update...

Policy / Regulatory

China’s NHC Releases Fourth List of Pediatric Priority Drugs to Boost Development

Fineline Cube May 26, 2023

The National Health Commission (NHC) of China has published its fourth list of pediatric drugs...

Company Drug

Sichuan Kelun Pharmaceutical to Present Clinical Data on RET Inhibitor and ADC at ASCO

Fineline Cube May 26, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a China-based pharmaceutical company, has unveiled plans to...

Policy / Regulatory R&D

Lancet Study Reveals Dalian’s Cancer Survival Rates Compared to US

Fineline Cube May 25, 2023

A recent study published in The Lancet has conducted a comparative analysis of cancer mortality...

Company Drug

BioRay Pharmaceutical’s LIV-1 Targeted ADC BRY812 Files IND in China

Fineline Cube May 25, 2023

Shanghai-based BioRay Pharmaceutical Co., Ltd has announced that an investigational new drug (IND) filing has...

Company Drug

Accropeutics Receives HREC Approval for AC-201 Phase I Trial

Fineline Cube May 25, 2023

Suzhou-based Accro Bioscience (Suzhou) Limited (Accropeutics) has announced that it has received approval from the...

Company Drug

Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis

Fineline Cube May 25, 2023

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced the imminent initiation...

Company Drug

Mabwell Bioscience’s 9MW3811 Receives NMPA Approval for Clinical Trials in Oncology and Fibrosis

Fineline Cube May 25, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical...

Company Drug

Roche’s Rozlytrek on Track for Priority Review for Pediatric NTRK Fusion Tumor Treatment

Fineline Cube May 25, 2023

The Center for Drug Evaluation (CDE) website has indicated that Roche’s (SWX: ROG) Rozlytrek (entrectinib)...

Company Deals

Zelixir Biotech Secures Over RMB 100 Million in Series A Financing for Synthetic Biology Pipeline

Fineline Cube May 25, 2023

Shanghai-based Zelixir Biotech, a leading provider of protein structure prediction and design services, has reportedly...

Company Deals

PathoAI Secures Tens of Millions in Angel Financing for AI-Powered Pathology Solutions

Fineline Cube May 25, 2023

PathoAI, a company at the forefront of intelligent pathology and examination through artificial intelligence (AI),...

Posts pagination

1 … 543 544 545 … 688

Recent updates

  • Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline
  • Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster
  • Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP
  • Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients
  • Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.